Next Article in Journal / Special Issue
Inconclusive Diagnosis after Newborn Screening for Cystic Fibrosis
Previous Article in Journal
Determining Reference Ranges for Total T4 in Dried Blood Samples for Newborn Screening
Previous Article in Special Issue
History of Newborn Screening for Cystic Fibrosis—The Early Years
Review

Newborn Screening for CF across the Globe—Where Is It Worthwhile?

1
Inserm, University of Brest, EFS, UMR 1078, GGB, F-29200 Brest, France
2
Department of Pediatrics, University of Alabama at Birmingham, Birmingham, AL 35233, USA
3
Departments of Pediatrics and Population Health Sciences, University of Wisconsin School of Medicine and Public Health, Madison, WI 53705, USA
*
Author to whom correspondence should be addressed.
Int. J. Neonatal Screen. 2020, 6(1), 18; https://doi.org/10.3390/ijns6010018
Received: 31 January 2020 / Revised: 20 February 2020 / Accepted: 24 February 2020 / Published: 4 March 2020
(This article belongs to the Special Issue Newborn Screening for Cystic Fibrosis)
Newborn screening (NBS) for cystic fibrosis (CF) has been performed in many countries for as long as four decades and has transformed the routine method for diagnosing this genetic disease and improved the quality and quantity of life for people with this potentially fatal disorder. Each region has typically undertaken CF NBS after analysis of the advantages, costs, and challenges, particularly regarding the relationship of benefits to risks. The very fact that all regions that began screening for CF have continued their programs implies that public health and clinical leaders consider early diagnosis through screening to be worthwhile. Currently, many regions where CF NBS has not yet been introduced are considering options and in some situations negotiating with healthcare authorities as policy and economic factors are being debated. To consider the assigned question (where is it worthwhile?), we have completed a worldwide analysis of data and factors that should be considered when CF NBS is being contemplated. This article describes the lessons learned from the journey toward universal screening wherever CF is prevalent and an analytical framework for application in those undecided regions. In fact, the lessons learned provide insights about what is necessary to make CF NBS worthwhile. View Full-Text
Keywords: cystic fibrosis; newborn screening; incidence; malnutrition; cost; health policy cystic fibrosis; newborn screening; incidence; malnutrition; cost; health policy
Show Figures

Figure 1

MDPI and ACS Style

Scotet, V.; Gutierrez, H.; Farrell, P.M. Newborn Screening for CF across the Globe—Where Is It Worthwhile? Int. J. Neonatal Screen. 2020, 6, 18. https://doi.org/10.3390/ijns6010018

AMA Style

Scotet V, Gutierrez H, Farrell PM. Newborn Screening for CF across the Globe—Where Is It Worthwhile? International Journal of Neonatal Screening. 2020; 6(1):18. https://doi.org/10.3390/ijns6010018

Chicago/Turabian Style

Scotet, Virginie, Hector Gutierrez, and Philip M. Farrell. 2020. "Newborn Screening for CF across the Globe—Where Is It Worthwhile?" International Journal of Neonatal Screening 6, no. 1: 18. https://doi.org/10.3390/ijns6010018

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop